Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325635 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL8152254 | 0.82 | MEN1 (0.43) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL4278377 | 0.80 | CYP1A2 (0.47) | SMN1; SMN2MAPTMEN1KMT2ANCF1 | |
| SCHEMBL1131286 | 0.76 | NCF1 (0.50) | SMN1; SMN2MAPTMEN1KMT2ANCF1 | |
| SCHEMBL31498821 | 0.76 | NCF1 (0.50) | SMN1; SMN2MAPTMEN1KMT2ANCF1 | |
| SCHEMBL6607250 | 0.76 | MEN1 (0.51) | SMN1; SMN2MAPTMEN1KMT2ANCF1 | |
| SCHEMBL18635305 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2HTTMAPTMEN1KMT2A | |
| SCHEMBL2744806 | 0.76 | CYP1A2 (0.42) | SMN1; SMN2MAPTMEN1KMT2ANCF1 | |
| SCHEMBL21224724 | 0.74 | HTT (0.55) | SMN1; SMN2HTTMEN1KMT2ACYP1A2 | |
| SCHEMBL31184081 | 0.74 | HTT (0.55) | SMN1; SMN2HTTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | claimed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| US-9801878-B2 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2017-10-31 | — | — | US | disclosed |
| US-20160303120-A1 | Quinoline Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2016-10-20 | — | — | US | disclosed |
| US-20150376186-A1 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-9216986-B1 | Quinoline derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-12-22 | — | — | US | disclosed |
| EP-2794606-A1 | QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2014-10-29 | — | — | EP | disclosed |
| CN-103930418-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-07-16 | — | — | CN | disclosed |
| CN-103857675-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-06-11 | — | — | CN | disclosed |
| WO-2013092974-A1 | QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1009748-A1 | 3-ALKYLPYRROLO 3,2-$i(c)]QUINOLINE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 2000-06-21 | — | — | EP | disclosed |
| WO-2000001696-A1 | 3-ALKYLPYRROLO[3,2-c]QUINOLINE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | SMN1; SMN2 3884/4885HTT 3965/4885MAPT 2230/4885 |
| US-20150376186-A1 | Quinoline derivatives as PDE10A enzyme inhibitors | PDE5A, PDE12, PDE3B | SMN1; SMN2 1254/4885HTT 787/4885MAPT 664/4885 |
| US-20160303120-A1 | Quinoline Derivatives as PDE10A Enzyme Inhibitors | PDE5A, PDE3B, PDE12 | SMN1; SMN2 1213/4885HTT 680/4885MAPT 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.